Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Trojan Horse Treatment Based on Peg-Coated Extracellular Vesicles to Deliver Doxorubicin to Melanoma in Vitro and in Vivo

Version 1 : Received: 10 May 2021 / Approved: 11 May 2021 / Online: 11 May 2021 (10:19:50 CEST)

How to cite: Patras, L.I.; Ionescu, A.E.; Munteanu, C.V.A.; Hajdu, R.; Kosa, A.C.; Porfire, A.; Licarete, E.; Rauca, V.F.; Sesarman, A.; Luput, L.; Bulzu, P.; Chiroi, P.; Tranca, R.A.; Meszaros, M.S.; Negrea, G.; Barbu-Tudoran, L.; Potara, M.; Szedlacsek, S.S.; Banciu, M. Trojan Horse Treatment Based on Peg-Coated Extracellular Vesicles to Deliver Doxorubicin to Melanoma in Vitro and in Vivo. Preprints 2021, 2021050229 (doi: 10.20944/preprints202105.0229.v1). Patras, L.I.; Ionescu, A.E.; Munteanu, C.V.A.; Hajdu, R.; Kosa, A.C.; Porfire, A.; Licarete, E.; Rauca, V.F.; Sesarman, A.; Luput, L.; Bulzu, P.; Chiroi, P.; Tranca, R.A.; Meszaros, M.S.; Negrea, G.; Barbu-Tudoran, L.; Potara, M.; Szedlacsek, S.S.; Banciu, M. Trojan Horse Treatment Based on Peg-Coated Extracellular Vesicles to Deliver Doxorubicin to Melanoma in Vitro and in Vivo. Preprints 2021, 2021050229 (doi: 10.20944/preprints202105.0229.v1).

Abstract

Tailoring extracellular vesicles (EVs) as targeted drug delivery systems to enhance the therapeutic efficacy showed superior advantage over liposomal therapies. Herein, we developed a novel nanotool for targeting B16.F10 murine melanoma, based on EVs stabilized with Polyethylene glycol (PEG) and loaded with doxorubicin (DOX). Nanosized EVs were efficiently enriched from melanoma cells cultured under metabolic stress by ultrafiltration coupled with size exclusion chromatography (UF-SEC) and characterized by size, morphology, and proteome. To reduce their clearance in vivo, EVs were PEGylated and passively loaded with DOX (PEG-EV-DOX). Our data suggested that the low PEG coverage of EVs might still favor EV surface protein interactions with target proteins from intratumor cells, ensuring their use as “Trojan horses” to deliver DOX to the tumor tissue. Moreover, our results showed a superior antitumor activity of PEG-EV-DOX in B16.F10 murine melanoma models in vitro and in vivo compared to that exerted by clinically applied liposomal DOX in the same tumor model. The PEG-EV-DOX administration in vivo reduced NF-κB activation and increased BAX expression, suggesting better prognosis of EV-based therapy than liposomal DOX treatment. Collectively, our results highlight the promising potential of EVs as optimal tools for systemic delivery of DOX to solid tumors.

Keywords

extracellular vesicles; melanoma; doxorubicin; drug delivery systems.

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.